



Eisai Co., Ltd.

treatment option for patients with thrombocytopenia, as well as increase its contributions to patients in China, India and other countries with a high incidence of hepatitis.

Through this acquisition, Eisai will further enhance its portfolio of pipeline products, and will make contributions towards increasing benefits of patients and their families by addressing the unmet medical needs.

In accordance with the acquisition, Eisai has revised its full-year consolidated business forecast for the fiscal year ending March 31, 2010, (April 1, 2009 to March 31, 2010) as outlined below.

1. Revised full-year consolidated business forecast for the fiscal year ending March 31, 2010 (April 1, 2009 to March 31, 2010)

(unit: million yen)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)	820,000	103,000	97,000	63,000

3. Year-end dividend forecast

In cash-flow, the expense that will occur in association with the acquisition of AkaRx, will be accounted as cash-flow used in investment activities and will not affect cash income,* which expresses the company's ability to generate cas

<Notes to Editors>

> **Outline of AkaRx, Inc.**

Location: Bridgewater, New Jersey, United States

CEO: Dr. Robert E. Desjardins

Establishment: December 1, 2004

Pipeline Product: AKR-501

> **About AKR-501**

AKR-501 (current research code: E5501) is a pharmacological agonist of the receptors of thrombopoietin (TPO), which stimulates platelet production acting on megakaryocytes and their precursors. When administered orally, this novel compound is expected to demonstrate its effects in various diseases associated with thrombocytopenia by promoting an increase in platelet count. Eisai is currently conducting Phase II clinical studies of the compound in the United States for idiopathic thrombocytopenic purpura (ITP) and thrombocytopenia associated with liver diseases, and has confirmed POC (Proof of Concept) in the clinical studies for ITP.

> **About Idiopathic Thrombocytopenic Purpura (ITP)**

Idiopathic thrombocytopenic purpura (ITP) is a disorder that causes a variety of bleeding symptoms due to a decrease in platelet count caused by